Stay updated on Daratumumab for AML/High-Risk MDS Clinical Trial
Sign up to get notified when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.

Latest updates to the Daratumumab for AML/High-Risk MDS Clinical Trial page
- CheckyesterdayChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page. No changes to study data or page navigation are indicated.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedAdded Revision: v3.4.2. Removed the notice about lapse in government funding and the previous Revision: v3.4.1 entry.SummaryDifference0.5%

- Check37 days agoChange DetectedAdded a government funding lapse notice and a page revision indicator (v3.4.1). Removed the previous revision indicator (v3.4.0).SummaryDifference0.5%

- Check44 days agoChange DetectedShow glossary was added and labels related to QC updates and No FEAR Act data were adjusted, with the revision tag updated to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check58 days agoChange DetectedRevision note updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check80 days agoChange DetectedLocations section added, listing Texas (MD Anderson Cancer Center) as a site. The Texas Locations heading and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

Stay in the know with updates to Daratumumab for AML/High-Risk MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab for AML/High-Risk MDS Clinical Trial page.